Frequent readmissions after hospitalization for alcohol withdrawal: a systematic review and meta-analysis.

Addict BehavAug 1, 2026 (epub)
Clinical ResearchInternal Medicine (General)Psychiatry

Tatyana D Fedorova, Helene Seegert, Mikael Beck et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined readmission rates after inpatient detoxification for alcohol use disorder. Among 25 studies, the pooled readmission rate was 17% within 1 month and 44% within 1 year. The analysis highlighted significant variability in readmission rates across different settings and populations.

Key findings

  • The pooled readmission rate was 17% within 1 month after detoxification.
  • Readmission rates increased to 44% within 1 year post-detoxification.
  • Substantial heterogeneity was observed between studies regarding readmission rates.
  • Limited data suggested associations with housing stability, employment, and treatment engagement.

Why it matters

Understanding readmission rates following alcohol detoxification is crucial for clinicians to identify high-risk patients and develop strategies to improve long-term outcomes. This knowledge can inform targeted interventions to reduce the burden of repeated hospitalizations.

Source

PubMed · PMID 42551121

Published in Addict Behav. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Internal Medicine (General)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.